This performance was largely driven by the impressive growth of REZLIDHIA, the company’s mIDH1 inhibitor for relapsed/refractory acute myeloid leukemia (AML), which saw a 107% year-over-year increase.

The FDA's Substances Generally Recognized as Safe -- or GRAS -- rule will be revised to enhance the agency's oversight of ingredients and provide transparency for American consumers. HHS also ...

The junk food that fits his budget but feels addictive and makes him feel unwell. Shea, one of 1,310 people who responded to a poll the health policy research group KFF conducted on health care ...

Copyright 2025 The Associated Press. All Rights Reserved. Elon Musk, center left, operating with a directive from President Donald Trump to slash government spending ...

Shea, one of 1,310 people who responded to a poll the health policy research group KFF conducted on health care priorities, said he assumes the FDA is making sure the ingredients are safe.

Kennedy Jr., another crucial governmental health leadership nominee—the proposed head of the FDA—took center stage Thursday. At his confirmation hearing before the Senate’s Health ...

A key lab that oversees US pharmaceutical safety is in limbo following moves by the Department of Government Efficiency, raising questions about the fate of the lab and the new administration’s ...

*NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. Total costs and expenses were ...

REZLIDHIA more than doubled both bottles shipped ... dependent lower-risk MDS and orphan drug designation for MDS by the FDA. Furthermore, as part of Rigel-sponsored development programs and ...

REZLIDHIA is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an ...